MYC and breast cancer: Bioinformatic analysis of the METABRIC breast cancer database of ~2000 patient tumour samples showed that MYC is indeed most highly expressed in claudin-low (CL) and basal breast cancers, which are also the two subtypes most highly enriched for TNBCs (Fig. 5a).1,2,23,24 However, CL breast cancers specifically had the highest expression of CD36, LPL, and PDGFRB (Fig. 5b–d).